- Country: Panama
- Summary: R-1: Amphotericin B, 50 Mg, Lyophilized Powder Sheet 10346 / R-2: Gentamicin Sulfate Ampoule Or Vial, 40mg/Ml, 2ml, Im; Iv Schedule 10142 / R-3: Valganciclovir, 450 Mg, Tablet, Vo Schedule 11885
- PAT Ref No: 87783675
- Deadline: 04 Sep 2023
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: PAB 10410.39
- Notice Type: Tender
- Document Ref. No.:
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Tenders Are Invited R-1: Amphotericin B, 50 Mg, Lyophilized Powder Sheet 10346 / R-2: Gentamicin Sulfate Ampoule Or Vial, 40mg/Ml, 2ml, Im; Iv Schedule 10142 / R-3: Valganciclovir, 450 Mg, Tablet, Vo Schedule 11885
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINR-1: Amphotericin B, 50 Mg, Lyophilized Powder Sheet 10346 / R-2: Gentamicin Sulfate Ampoule Or Vial, 40mg/Ml, 2ml, Im; Iv Schedule 10142 / R-3: Valganciclovir, 450 Mg, Tablet, Vo Schedule 11885 - Panama Tender
The MINISTRY OF HEALTH, a Government sector organization in Panama, has announced a new tender for R-1: Amphotericin B, 50 Mg, Lyophilized Powder Sheet 10346 / R-2: Gentamicin Sulfate Ampoule Or Vial, 40mg/Ml, 2ml, Im; Iv Schedule 10142 / R-3: Valganciclovir, 450 Mg, Tablet, Vo Schedule 11885. This tender is published on PanamaTenders under PAT Ref No: 87783675 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2023-09-04.
The estimated tender value is PAB 10410.39, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
